

CITATION REPORT

List of articles citing

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

DOI: 10.1038/s41568-019-0133-9

Nature Reviews Cancer, 2019, 19, 289-297.

Source: <https://exaly.com/paper-pdf/73600330/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
519	Report from the ASCO 2019 Congress, Chicago, May 31st June 4th 2019. 2019 , 12, 45-64		
518	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. 2019 , 9, 1372-1387		74
517	Monosaccharide Analogues of Anticancer Peptide R-Lycosin-I: Role of Monosaccharide Conjugation in Complexation and the Potential of Lung Cancer Targeting and Therapy. 2019 , 62, 7857-7873		9
516	Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer. 2019 , 11,		6
515	Liquid biopsy tracking of lung tumor evolutions over time. 2019 , 19, 1099-1108		34
514	Systems-level network modeling of Small Cell Lung Cancer subtypes identifies master regulators and destabilizers. 2019 , 15, e1007343		33
513	DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. 2019 , 138, 102-108		18
512	Histologically Transformed SCLC From EGFR-Mutant NSCLC: Understanding the Wolf in Sheep's Clothing. 2019 , 14, 1689-1691		5
511	Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?. 2019 , 8, LMT13		14
510	Modeling heterogeneous tumor growth dynamics and cell-cell interactions at single-cell and cell-population resolution. 2019 , 17, 24-34		12
509	PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?. 2019 , 14, 1323-1326		4
508	Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. 2019 , 14, 2152-2163		48
507	Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?. 2019 , 9, 1340-1342		4
506	MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. 2019 , 25, 5107-5121		56
505	Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities. 2019 , 8, S430-S434		9
504	Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC.. 2019 , 3, 1-8		3
503	Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c Conventional Dendritic Cell Subsets Mediated by CD103 and CD205. 2019 , 10, 2829		5

502	Recent progress in mapping the emerging landscape of the small-cell lung cancer genome. 2019 , 51, 1-13	38
501	Classification and Imaging Findings of Lung Neoplasms. 2020 , 55, 41-50	1
500	Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. 2020 , 25, 831-841	14
499	Allosteric mechanism of an oximino-piperidino-piperidine antagonist for the CCR5 chemokine receptor. 2020 , 95, 113-123	0
498	In Search of the Long-Desired Copernican Therapeutic Revolution in Small-Cell Lung Cancer. 2020 , 80, 241-262	5
497	Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors. 2020 , 26, 6215-6229	9
496	An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients. 2020 , 12,	2
495	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. 2020 , 33, 108296	32
494	Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. 2020 , 150, 90-96	5
493	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. 2020 , 15, 1823-1835	63
492	ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer. 2020 , 12, 63	17
491	NOTCH Your Usual Suspect: MYC Charged with Controlling Neuroendocrine Cell-Fate in Small Cell Lung Cancer. 2020 , 38, 17-20	2
490	DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies as a Predictive Biomarker of VOLASERTIB in Small Cell Lung Carcinoma (SCLC). 2020 , 12,	2
489	Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors. 2020 , 10,	4
488	How should molecular findings be integrated in the classification for lung cancer?. 2020 , 9, 2245-2254	3
487	Genomic Profiling and Clinicopathological Characteristics of Neuroendocrine Tumors of the Lung in East Asian Patients. 2020 , 34, 3375-3385	2
486	Drugs in development for small cell lung cancer. 2020 , 12, 6298-6307	7
485	Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. 2020 ,	11

484	Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancer. 2020 , 12, 6264-6274	1
483	Reassessing the SCLC Subtypes. 2020 , 15, 1819-1822	2
482	New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. 2020 , 9, 2233-2244	25
481	Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants. 2020 , 150, 216-220	3
480	Systemic therapy for limited stage small cell lung carcinoma. 2020 , 12, 6275-6290	7
479	Immunotherapy for extensive stage small cell lung cancer. 2020 , 12, 6212-6224	2
478	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. 2020 , 80, 562-577	12
477	Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer. 2020 , 10, 1161	2
476	Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors. 2020 , 25, 353-366	1
475	Comprehensive Analysis of LincRNAs in Classical and Basal-Like Subtypes of Pancreatic Cancer. 2020 , 12,	2
474	Cells of origin of lung cancers: lessons from mouse studies. 2020 , 34, 1017-1032	36
473	Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. 2020 , 9,	6
472	Role of mTOR As an Essential Kinase in SCLC. 2020 , 15, 1522-1534	4
471	The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report. 2020 , 15, 1836-1843	21
470	Drug efficacy and toxicity prediction: an innovative application of transcriptomic data. 2020 , 36, 591-602	1
469	Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer. 2020 , 21, 527-533	5
468	Distinct transcriptional programs of SOX2 in different types of small cell lung cancers. 2020 , 100, 1575-1588	4
467	Biological functions of long noncoding RNAs and circular RNAs in small-cell lung cancer. 2020 , 12, 1751-1763	2

466	Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials. 2020 , 12,	21
465	Immunotherapy in Small Cell Lung Cancer. 2020 , 12,	19
464	drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity. 2020 , 34, 1210-1226	10
463	Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer. 2020 , 10, 1783	0
462	An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. 2020 , 183, 1420-1435.e21	39
461	Harnessing Natural Killer Immunity in Metastatic SCLC. 2020 , 15, 1507-1521	23
460	Integrating Genetic and Genomic Testing Into Oncology Practice. 2020 , 40, e259-e263	3
459	MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. 2020 , 38, 60-78.e12	92
458	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. 2020 , 38, 2369-2379	160
457	NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. 2020 , 146, 97-104	6
456	Profiling DNA mutation patterns by SERS fingerprinting for supervised cancer classification. 2020 , 165, 112392	20
455	ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation. 2020 , 123, 819-832	5
454	Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases: A Call for Prospective Evidence. 2020 , 6, 1037-1038	5
453	NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer. 2020 , 146, 154-159	9
452	Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. 2020 , 14, 1947-1965	14
451	ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma. 2020 , 489, 121-132	5
450	Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. 2020 , 38, 129-143.e7	22
449	Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells. 2020 , 153, 443-456	10

448	Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. 2020 , 210, 107522	26
447	MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X expression. 2020 , 11, 177	13
446	Lineage plasticity in cancer: a shared pathway of therapeutic resistance. 2020 , 17, 360-371	94
445	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. 2020 , 21, 645-654	99
444	Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. 2020 , 9, 1773205	1
443	Identification key genes, key miRNAs and key transcription factors of lung adenocarcinoma. 2020 , 12, 1917-1933	5
442	Slicing and dicing small cell lung cancer to improve trial outcomes. 2020 , 126, 3919-3921	
441	Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. 2020 , 126, 4002-4012	4
440	Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. 2020 , 12, 93	20
439	Pre-clinical models of small cell lung cancer and the validation of therapeutic targets. 2020 , 24, 187-204	2
438	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. 2020 , 15, 520-540	42
437	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). 2020 , 22, 245-255	20
436	Immunotherapeutic approaches for small-cell lung cancer. 2020 , 17, 300-312	86
435	The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer. 2020 , 80, 1293-1303	22
434	The powerful world of antisense oligonucleotides: From bench to bedside. 2020 , 11, e1594	69
433	A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity.. 2020 , 1, 437-451	45
432	The therapy escapes of small-cell lung cancer.. 2020 , 1, 374-375	2
431	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. 2021 , 15, 27-42	6

430	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. 2021 , 11,	8
429	Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer. 2021 , 29, 1-11	4
428	Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer. 2021 , 15, 195-209	6
427	Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery. 2021 , 108, 84-92	1
426	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. 2021 , 16, 464-476	23
425	The lung cancer stem cell niche. 2021 , 85-136	
424	Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. 2021 , 22, 51-65	101
423	CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics. 2021 , 49, D1083-D1093	23
422	Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer. 2021 , 12, 40-47	2
421	Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. 2021 , 27, 759-774	9
420	2020 Innovation-Based Optimism for Lung Cancer Outcomes. 2021 , 26, e454-e472	4
419	CADM1 promotes malignant features of small-cell lung cancer by recruiting 4.1R to the plasma membrane. 2021 , 534, 172-178	4
418	Clinical implications of lung neuroendocrine neoplasm classification. 2021 , 21, 377-387	0
417	Evaluation of Hippo Pathway and CD133 in Radiation Resistance in Small-Cell Lung Cancer. 2021 , 2021, 8842554	1
416	Morphologic and molecular classification of lung neuroendocrine neoplasms. 2021 , 478, 5-19	8
415	Cancer Hallmarks Define a Continuum of Plastic Cell States between Small Cell Lung Cancer Archetypes.	2
414	Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer. 2021 , 9,	1
413	Assessment of ENDPs in Animal Models of Disease. 2021 , 319-365	

412	Therapeutic Advances in Small Cell Lung Cancer Management. 2021 , 175-195	
411	An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer. 2021 , 13, 17588359211020529	3
410	Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. 2021 , 131,	15
409	DNA methylation integratedly modulates the expression of Pit-Oct-Unt transcription factors in esophageal squamous cell carcinoma. 2021 , 12, 1634-1643	4
408	Spatial Epitope Barcoding Reveals Subclonal Tumor Patch Behaviors.	0
407	Advances in novel molecular typing and precise treatment strategies for small cell lung cancer. 2021 , 33, 522-534	5
406	Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis. 2021 , 81, 1813-1826	14
405	Small Cell Lung Cancer: Biology Advances. 2021 , 197-211	
404	Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. 2021 , 32, 192-210	24
403	Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer. 2021 , 7,	10
402	First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions. 2021 , 6, 100003	5
401	PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses. 2021 , 13,	7
400	Pathology and Classification of SCLC. 2021 , 13,	13
399	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. 2021 , 13,	14
398	The landscape of small cell lung cancer metastases: Organ specificity and timing. 2021 , 12, 914-923	3
397	Fragmentation of Small-Cell Lung Cancer Regulatory States in Heterotypic Microenvironments. 2021 , 81, 1853-1867	7
396	Developmental Insights into Lung Cancer. 2021 , 5, 351-369	1
395	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. 2021 , 11, 1952-1969	12

394	RNA-based therapies: A cog in the wheel of lung cancer defense. 2021 , 20, 54	17
393	Targeting netrin-3 in small cell lung cancer and neuroblastoma. 2021 , 13, e12878	4
392	Topological signatures in regulatory network enable phenotypic heterogeneity in small cell lung cancer. 2021 , 10,	11
391	Molecular profiles of small cell lung cancer subtypes: therapeutic implications. 2021 , 20, 470-483	13
390	Small cell lung cancer enters the era of precision medicine. 2021 , 39, 297-299	5
389	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. 2021 , 39, 346-360.e7	107
388	Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. 2021 , 4, 314	9
387	Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives. 2021 , 13,	1
386	Transcription Factors and Regulators Involved in Cell Differentiation in Lung Tumor: Their Biological Significance and Role in the Pathological Diagnosis. 2021 , 61, 77-87	1
385	Gene Amplification-Associated Overexpression of the Selenoprotein tRNA Enzyme TRIT1 Confers Sensitivity to Arsenic Trioxide in Small-Cell Lung Cancer. 2021 , 13,	1
384	Small Cell Lung Cancer: State of the Art of the Molecular and Genetic Landscape and Novel Perspective. 2021 , 13,	4
383	Distinct patterns of somatic genomic alterations and mutational signatures in central and peripheral-type small-cell lung cancer. 2021 , 10, 1747-1760	1
382	Thoracic radiotherapy in small cell lung cancer-a narrative review. 2021 , 10, 2059-2070	2
381	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. 2021 , 39, 566-579.e7	24
380	Abnormal spindle-like microcephaly-associated protein enhances cell invasion through Wnt/ β -catenin-dependent regulation of epithelial-mesenchymal transition in non-small cell lung cancer cells. 2021 , 13, 2460-2474	0
379	Promising Role of Circulating Tumor Cells in the Management of SCLC. 2021 , 13,	1
378	Stem cells and lung cancer. 2021 , 340-352	1
377	Gene Targeting in Disease Networks. 2021 , 12, 649942	3

376	Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy. 2021 , 2, 100164	2
375	Decoding Cancer Biology One Cell at a Time. 2021 , 11, 960-970	8
374	ASCL1 represses a SOX9 neural crest stem-like state in small cell lung cancer. 2021 , 35, 847-869	9
373	Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. 2021 , 27, 3884-3895	7
372	Neuroendocrine neoplasms of the lung: a pathology update. 1	0
371	Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas. 2021 , 35, 870-887	0
370	DNA Framework-based Topological Aptamer for Differentiating Subtypes of Hepatocellular Carcinoma Cells. 2021 , 37, 919-924	2
369	Cancer Testis Antigen, NOL4, Is an Immunogenic Antigen Specifically Expressed in Small-Cell Lung Cancer. 2021 , 28, 1927-1937	1
368	Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. 2021 , 10,	4
367	Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung. 2021 , 12, 577	1
366	In the literature: April 2021. 2021 , 6, 100116	
365	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. 2021 , 81, 3916-3929	2
364	Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. 2021 ,	13
363	Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. 2021 , 12, 3880	11
362	Small cell lung cancer: a slightly less orphan disease after immunotherapy. 2021 , 32, 698-709	11
361	Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. 2021 , 12, 3785	3
360	Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. 2021 , 10, 2788-2805	0
359	Immunotherapy in small cell lung cancer: one step at a time: a narrative review. 2021 , 10, 2970-2987	1

358	Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer. 2021 , 10,	4
357	A Tuft Cell-Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes. 2021 , 16, 1003-1016	10
356	FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis. 2021 , 40, 4847-4858	6
355	Spatial epitope barcoding reveals subclonal tumor patch behaviors.	0
354	De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small-cell lung carcinoma. 2021 , 11, 13474	2
353	Defining the functional divergence of orthologous genes between human and mouse in the context of miRNA regulation. 2021 , 22,	2
352	Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1. 2021 , 10, 3155-3172	5
351	Seven key hub genes identified by gene co-expression network in cutaneous squamous cell carcinoma. 2021 , 21, 852	7
350	Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. 2021 , 16, 1211-1223	4
349	Reframing recalcitrance for small-cell lung cancer. 2021 , 32, 829-830	0
348	A mesenchymal-like subpopulation in non-neuroendocrine SCLC contributes to metastasis. 2021 , 48, 571-581	
347	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. 2021 , 81, 4736-4750	2
346	Comprehensive analysis of prognostic predictors for patients with limited-stage small-cell lung cancer who underwent resection followed by adjuvant chemotherapy. 2021 , 9, 1169	
345	Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer. 2021 , 69, 103457	10
344	PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer. 2021 , 48, 640-651	4
343	Pre-diagnosis neutrophil-to-lymphocyte ratio and mortality in individuals who develop lung cancer. 2021 , 32, 1227-1236	3
342	Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities. 2021 , 15, 3545-3558	0
341	Recent developments in the treatment of small cell lung cancer. 2021 , 30,	7

340	Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis.	1
339	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. 2021 , 21, 757-766	1
338	Plasma Based Protein Signatures Associated with Small Cell Lung Cancer. 2021 , 13,	1
337	Overcoming Chemotherapy Resistance in SCLC. 2021 , 16, 2002-2015	3
336	Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. 2021 ,	3
335	Current concepts in the classification of thoracic neuroendocrine tumours. 2021 , 27, 336-343	
334	Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. 2021 , 39, 1115-1134.e12	19
333	Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment. 2021 , 15, 1415-1425	1
332	Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy. 2021 , 38, 113	3
331	Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer. 2021 , 1876, 188552	7
330	Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibition as Maintenance Treatment for SCLC: The Search Must Continue. 2021 , 16, 1236-1238	
329	PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer. 2021 , 81, 4696-4708	3
328	Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. 2021 , 9, 33	3
327	Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype. 2021 , 19, 2015-2025	1
326	MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex. 2021 , 118,	2
325	Recent advances and current controversies in lung neuroendocrine neoplasms. 2021 , 38, 90-97	2
324	Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. 2021 ,	3
323	Patient-Derived Xenografts to Study Cancer Metabolism: When Does X Mark the Spot?. 2021 , 81, 4399-4401	

322	Repositioning PARP inhibitors in the treatment of thoracic malignancies. 2021 , 99, 102256	0
321	All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC. 2021 , 16, 1429-1433	0
320	Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. 2021 , 11,	1
319	SCLC-J1, a novel small cell lung cancer cell line. 2021 , 27, 101089	
318	Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. 2021 , 255, 425-437	2
317	ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer. 2021 , 24, 102953	3
316	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. 2021 , 1	0
315	Simplifying cancer: binary pan-cancer superclasses stratified by opposite YAP/TEAD effects. 2021 , 8, 1981111	0
314	Clinical-Pathologic Challenges in the Classification of Pulmonary Neuroendocrine Neoplasms and Targets on the Horizon for Future Clinical Practice. 2021 , 16, 1632-1646	9
313	YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes. 2021 , 160, 166-174	2
312	The differentiation of new human CD303 Plasmacytoid dendritic cell subpopulations expressing CD205 and/or CD103 regulated by Non-Small-Cell lung cancer cells. 2021 , 99, 107983	
311	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. 2021 , 12, 5775	6
310	YAP drives fate conversion and chemoresistance of small cell lung cancer. 2021 , 7, eabg1850	5
309	Small-cell lung cancer. 2021 , 7, 3	102
308	Una nomenclatura universale per le neoplasie neuroendocrine. 2021 , 22, 1-7	
307	MicroRNAs Involved in Small-cell Lung Cancer as Possible Agents for Treatment and Identification of New Targets. 2021 , 18, 591-603	0
306	Thoracic (Lung/Thymus) Neuroendocrine Neoplasms. 2021 , 151-206	1
305	Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung. 2020 , 23, 100167	3

304	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. 2020 , 1, 423-436	88
303	SCLC_CellMiner: Integrated Genomics and Therapeutics Predictors of Small Cell Lung Cancer Cell Lines based on their genomic signatures.	1
302	Lineage transcription factors co-regulate subtype-specific genes providing a roadmap for systematic identification of small cell lung cancer vulnerabilities.	3
301	Topological signatures in regulatory network enable phenotypic heterogeneity in small cell lung cancer.	1
300	ASCL1 represses a latent osteogenic program in small cell lung cancer in multiple cells of origin.	1
299	Single cell profiling reveals novel tumor and myeloid subpopulations in small cell lung cancer.	2
298	The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy. 2020 , 15, e0240973	7
297	Mechanisms of small cell lung cancer metastasis. 2021 , 13, e13122	21
296	NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer. 2020 , 11, 3590-3600	2
295	Axon-like protrusions promote small cell lung cancer migration and metastasis. 2019 , 8,	17
294	Cancer bronchique \square petites cellules : quoi de neuf ?. 2021 , 13, 2S185-2S192	
293	Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium. 2021 ,	3
292	Immunotherapy in Extensive-Stage Small Cell Lung Cancer. 2021 , 28, 4093-4108	2
291	Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. 2021 , 11, 757323	3
290	Lung neuroendocrine neoplasms: recent progress and persistent challenges. 2021 ,	11
289	Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. 2021 , 39, 1479-1496.e18	11
288	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. 2021 , 14, 170	3
287	In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma. 2021 ,	3

286	Treatment of small cell lung cancer: recent advances. 2022 , 34, 83-88	0
285	BET Bromodomain Inhibitors Target the NEUROD1-subtype SCLC by Blocking NEUROD1 Transactivation.	0
284	NeuroD1 promotes tumor cell proliferation and tumorigenesis by directly activating the pentose phosphate pathway in colorectal carcinoma. 2021 ,	0
283	Regulation of Neuroendocrine Plasticity by the RNA-Binding Protein ZFP36L1.	1
282	The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer. 2021 ,	0
281	Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report. 2021 , 15, 261	1
280	Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma. 2021 , 13,	0
279	What Are the Biomarkers for Immunotherapy in SCLC?. 2021 , 22,	2
278	Application of Single-Cell Multi-Omics in Dissecting Cancer Cell Plasticity and Tumor Heterogeneity. 2021 , 8, 757024	3
277	MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. 2021 , 24, 103224	4
276	Advances in Preclinical Models of Small Cell Lung Cancer. 2019 ,	2
275	Sox2 is an oncogenic driver of small cell lung cancer.	
274	Axon-like protrusions promote small cell lung cancer migration and metastasis.	0
273	Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.	
272	Discriminative Subtyping of Lung Cancers from Histopathology Images via Contextual Deep Learning.	1
271	Relationship Between Neuroendocrine and Immune Gene Expression in Small Cell Lung Cancer.	
270	Computational analysis reveals similarities and differences between SCLC subtypes.	
269	Encyclopedia of Pathology. 2020 , 1-7	

268	Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation.	3
267	Neuroendocrine Lung Cancer Mouse Models: An Overview. 2020 , 13,	0
266	Using iPSC-Based Models to Understand the Signaling and Cellular Phenotypes in Idiopathic Autism and 16p11.2 Derived Neurons. 2020 , 25, 79-107	0
265	Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution.	
264	Fragmentation of Small-cell Lung Cancer Regulatory States in Heterotypic Microenvironments.	2
263	Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state. 2021 ,	4
262	Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer. 2021 , 11, 744724	6
261	Molecular Pathology of Lung Cancer. 2021 ,	1
260	Chromatin accessibility profiles of castration-resistant prostate cancers reveal novel subtypes and therapeutic vulnerabilities.	0
259	Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer.	2
258	Harnessing the Immune System to Tackle Small Cell Lung Cancer. 2020 , 26, 502-506	
257	Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer.	
256	Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities.	
255	Rho-kinase inhibition by Fasudil promotes tumor maturation and apoptosis in small-cell lung cancer. 2020 , 12, 4354-4370	1
254	[Highlights of PPAR Inhibitors in Small Cell Lung Cancer]. 2020 , 23, 806-810	
253	Recent advances in lung cancer genomics: Application in targeted therapy. 2021 , 108, 201-275	0
252	Prognostic value and non-neuroendocrine role of INSM1 in small cell lung cancer. 2021 , 229, 153693	0
251	PPDPF Promotes the Progression and acts as an Antiapoptotic Protein in Non-Small Cell Lung Cancer.. 2022 , 18, 214-228	0

250	The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. 2021,	26
249	Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy. 2021,	0
248	Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. 2021, 12, 6652	1
247	TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change. 2021, 37, 109979	2
246	alteration in -mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment.. 2021, 10, 4161-4173	0
245	Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment.. 2021, 10, 4209-4220	0
244	Economic assessment of molecular imaging in the oncology treatment process.. 2021, 146, 110105	
243	Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge review.. 2022, 1	1
242	Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.. 2021, 7, 100308	2
241	c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation.. 2022, 14,	2
240	Single-Cell Transcriptomic Analyses of Tumor Ecosystems and Spatial Architectures in Human Small Cell Lung Cancer.	
239	The role of YAP1 in small cell lung cancer.. 2022, 1	1
238	Expanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinoma.. 2022,	2
237	Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity.. 2022,	0
236	Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis.	1
235	RB1, Cancer Lineage Plasticity, and Therapeutic Resistance. 2022, 6,	0
234	Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.. 2022, JCO2101881	3
233	Molecular Knowledge and Clinical Relevance - Stepping Stones in Improving Classification of Lung Neuroendocrine Neoplasms.. 2022, 17, e8-e10	

232	Natural compound library screening identifies Sanguinarine chloride for the treatment of SCLC by upregulating CDKN1A.. 2022 , 17, 101345	1
231	The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.. 2022 , 136, 197-222	4
230	Current Therapy and Development of Therapeutic Agents for Lung Cancer. 2022 , 100015	1
229	Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.. 2021 , 40, 1141	5
228	Potential of Stem Cells and CART as a Potential Polytherapy for Small Cell Lung Cancer.. 2021 , 9, 778020	1
227	Prognostic Significance of YAP1 Expression and its Association with Neuroendocrine Markers in Resected Pulmonary Large Cell Neuroendocrine Carcinoma (Lcnec).	
226	Predictive value of collagen in cancer.. 2022 , 154, 15-45	0
225	Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).. 2022 , 20, 54	1
224	Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.. 2022 ,	1
223	Second primary malignancies in oral tongue cancer: A Surveillance, Epidemiology, and End ResultBased analysis evaluating the basic characteristics, survival outcomes, and predictive factors.	
222	Therapeutic modalities in small cell lung cancer: a paradigm shift after decades of quiescence.. 2022 , 1-15	
221	Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer.. 2022 ,	0
220	Kinase Suppressor of Ras 2 regulates small-cell lung carcinoma tumor propagating cells.	
219	KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer.. 2022 , 8, eabl4618	0
218	Evolving role of immunotherapy in small cell lung cancer.. 2022 ,	3
217	Whole-Process Treatment of Combined Small Cell Lung Cancer Initially Diagnosed as "Lung Squamous Cell Carcinoma": A Case Report and Review of the Literature.. 2022 , 13, 831698	0
216	Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.. 2022 , e14841	1
215	Killing SCLC: insights into how to target a shapeshifting tumor.. 2022 , 36, 241-258	2

214	High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.. 2022,	2
213	The Origins of Merkel Cell Carcinoma: Defining Paths to the Neuroendocrine Phenotype.. 2021,	1
212	Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints.. 2022,	0
211	Network-based cancer heterogeneity analysis incorporating multi-view of prior information.. 2022,	0
210	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.. 2022, 33, 115-154	18
209	Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: perspectives for immunotherapy of SCLC.. 2022,	10
208	Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity.. 2022, 12, 779276	0
207	Neuroendocrinology of the lung revealed by single cell RNA sequencing.	0
206	A multiplexed in vivo approach to identify driver genes in small cell lung cancer.	
205	Transcriptional circuitry of NKX2-1 and SOX1 defines an unrecognized lineage subtype of small cell lung cancer.	
204	Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges.. 2022, 11,	0
203	Non-coding genome in small cell lung cancer between theoretical view and clinical applications.. 2022,	0
202	Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.. 2022, 7, 100408	4
201	Small cell lung cancer: Subtypes and therapeutic implications.. 2022,	0
200	Therapeutic targeting ROR α with natural product N-hydroxyapiosporamide for small cell lung cancer by reprogramming neuroendocrine fate.. 2022, 178, 106160	0
199	Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes.. 2022, 13, 1811	2
198	Cell plasticity in patients with NSCLC: The controversial origins of transformed SCLC. 2022, 149, 112909	0
197	De Novo G12C-Mutant SCLC: A Case Report.. 2022, 3, 100306	

196	Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. 2021 ,	2
195	Advances in ameliorating inflammatory diseases and cancers by andrographolide: Pharmacokinetics, pharmacodynamics, and perspective. 2021 ,	2
194	Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer.. 2021 , 11, e620	1
193	ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.. 2021 ,	1
192	Limited-Stage Small-Cell Lung Cancer: Current Progress and the Next Frontier. 2021 , 1, 317-333	
191	Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?. 2021 , 22,	0
190	Bisphenol-A/Radiation mediated inflammatory response activates EGFR/KRAS/ERK1/2 signaling pathway leads to lung carcinogenesis incidence.. 2022 , 36, 3946320221092918	
189	WNT5A-RHOA axis is a new vulnerability in small-cell lung cancer.	
188	Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models.. 2022 , 13, 2023	1
187	Identification of Immune Infiltration and Prognostic Biomarkers in Small Cell Lung Cancer Based on Bioinformatic Methods from 3 Studies.. 2022 ,	1
186	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts.. 2022 , 13, 2144	0
185	Genetic Alteration and Their Significance on Clinical Events in Small Cell Lung Cancer.. 2022 , 14, 1493-1505	0
184	Data_Sheet_1.doc. 2019 ,	
183	Table_1.DOCX. 2020 ,	
182	Table_2.DOCX. 2020 ,	
181	Table_3.XLSX. 2020 ,	
180	KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming.. 2022 ,	2
179	[Advances in Molecular Typing of Small Cell Lung Cancer]. 2021 , 24, 734-738	

178	Organoids as a Systems Platform for SCLC Brain Metastasis.. 2022 , 12, 881989	0
177	Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer: an international multicenter study.. 2022 ,	1
176	ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.. 2022 , 13, 2282	1
175	Genomic and immunological profiles of small-cell lung cancer between East Asians and Caucasian.. 2022 , 22, 173	2
174	Reducing Chemotherapy-Induced DNA Damage via nAChR-Mediated Redox Reprogramming-A New Mechanism for SCLC Chemoresistance Boosted by Nicotine.. 2022 , 14,	0
173	Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory.. 2022 ,	
172	A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs.. 2022 , 13, 2690	1
171	WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.. 2022 , 39, 110814	3
170	OCA-T1 and OCA-T2 are coactivators of POU2F3 in the tuft cell lineage.. 2022 ,	1
169	Pulmonary Neuroendocrine Cells and Small Cell Lung Carcinoma: Immunohistochemical Study Focusing on Mechanisms of Neuroendocrine Differentiation. 2022 ,	
168	Genomic features of Chinese small cell lung cancer. 2022 , 15,	0
167	Lymphocyte-to-monocyte ratio is an independent prognostic factor in surgically treated small cell lung cancer: An international multicenter analysis. 2022 , 169, 40-46	3
166	Gene-Networks analyses define a subgroup of Small Cell Lung Cancers with short survival. 2022 ,	
165	Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors.	0
164	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. 2022 , 376,	3
163	Molecular subtyping of small cell lung cancer. 2022 ,	0
162	N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma. 2022 , 22,	0
161	Molecular mechanisms underlying the development of neuroendocrine prostate cancer. 2022 ,	2

160	ABBV-011, A Novel, Calicheamicin-Based AntibodyDrug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors. 2022 , 21, 986-998	
159	Inhibition of karyopherin β -mediated nuclear import disrupts oncogenic lineage- defining transcription factor activity in small cell lung cancer.	
158	Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Nonneuroendocrine Small Cell Lung Cancer. OF1-OF12	2
157	POU2F3 in SCLC: Clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC. 2022 ,	2
156	Signal pathways and precision therapy of small-cell lung cancer. 2022 , 7,	1
155	Chemotherapy- and Immune-Related Gene Panel in Prognosis Prediction and Immune Microenvironment of SCLC. 10,	
154	Replication Stress Defines Distinct Molecular Subtypes Across Cancers. 2022 , 2, 503-517	0
153	Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer. 2022 , 25, 104576	0
152	Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes.	
151	Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. 2022 ,	1
150	ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.	0
149	Rb tumor suppressor in small cell lung cancer: Combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset..	2
148	DLL3 REGULATES NOTCH SIGNALING IN SCLC.	
147	Comprehensive genetic analysis of histological components of combined small cell carcinoma.	
146	CDK7 inhibition synergizes with topoisomerase I inhibition in small cell lung cancer cells by inducing ubiquitin-mediated proteolysis of RNA polymerase II.	0
145	Neuronal survival factor VGF promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature.	
144	SMYD3 impedes small cell lung cancer sensitivity to alkylation damage through RNF113A methylation-phosphorylation crosstalk.	
143	Improving the efficacy of immunotherapy in small cell lung cancer: Leveraging recent scientific discoveries and tumor-specific antigens. 2022 ,	

- 142 The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage Small Cell Lung Cancer. **2022**, 100373
- 141 Transcriptional Circuitry of NKX2-1 and SOX1 Defines an Unrecognized Lineage Subtype of Small Cell Lung Cancer. 1
- 140 p53 restoration in small cell lung cancer identifies a latent Cyclophilin-dependent necrosis mechanism.
- 139 Unified Tumor Growth Mechanisms from Multimodel Inference and Dataset Integration.
- 138 Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation. 0
- 137 Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. **2022**, 0
- 136 Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1. **2022**, 13,
- 135 Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer. **2022**, 14, 3772 0
- 134 Organoids in lung cancer: a teenager with infinite growth potential. **2022**, 0
- 133 DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. 1
- 132 New Insights into the Epigenomic Landscape of Small Cell Lung Cancer: a Game Changer?.
- 131 Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics. 9, 1
- 130 cfDNA methylome profiling for detection and subtyping of small cell lung cancers. 1
- 129 Tuft cell-like carcinomas: novel cancer subsets present in multiple organs sharing a unique gene expression signature. 0
- 128 Insulinoma-Associated Protein 1 (INSM1): Diagnostic, Prognostic, and Therapeutic Use in Small Cell Lung Cancer. **2022**, 3, 140-169 0
- 127 YES1 is a druggable oncogenic target in Small Cell Lung Cancer. **2022**,
- 126 CircRNA circ-PDCD11 is highly expressed in lung large cell carcinoma and predicts poor survival. 1-19
- 125 Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy. **2022**, 14, 3953

124	Opportunities and challenges of immune checkpoint inhibitors for extensive-stage small-cell lung cancer.	0
123	Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer.	0
122	Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition.	1
121	Inhibition of LSD1 with bome demstat sensitizes small cell lung cancer to immune checkpoint blockade and T cell killing.	0
120	Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer. 2022,	2
119	Determining Whether YAP1 and POU2F3 Are Antineuroendocrine Factors. 2022, 17, 1070-1073	0
118	WNT5A-RHOA signaling is a driver of tumorigenesis and represents a therapeutically actionable vulnerability in small cell lung cancer.	0
117	Bench to bedside: recent advances in lung cancer pathological research with implications for diagnostic clinical practice. 2022,	0
116	Genetic variants of NEUROD1 target genes are associated with clinical outcomes of small-cell lung cancer patients.	0
115	Analysis of transcriptome datasets reveals involvement of epithelial-mesenchymal transition genes in small cell lung cancer phenotypic plasticity.	0
114	Prognostic significance of YAP1 expression and its association with neuroendocrine markers in resected pulmonary large cell neuroendocrine carcinoma (LCNEC). 2022, 25, 101538	0
113	Chemotherapy for Lung Cancer. 2022,	0
112	Genomic Alterations in Lung Cancer. 2022,	0
111	Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function. 2022,	0
110	Epigenetic reprogramming in small cell lung cancer. 2022, 19, 1111-1116	0
109	Lurbinectedin in small cell lung cancer. 12,	1
108	Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets. 2022, 2, 186-244	0
107	Exploring Molecular Subtypes of Small-Cell Lung Cancer and Other Pulmonary Neuroendocrine Carcinomas. 2022, 62, 286-291	0

- 106 To Rb or Not to Rb: Uncovering Unique Subsets of Small Cell Lung Carcinoma. OF1-OF3 ○
- 105 Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations. **2022**, 1877, 188798 ○
- 104 Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibits small-cell lung cancer growth without causing on-target toxicities in mice. ○
- 103 Overexpression of INSM1, NOTCH1, NEUROD1, and YAP1 genes is associated with adverse clinical outcome in pediatric neuroblastoma. ○
- 102 Unraveling phenotypic plasticity and evolution in small cell lung cancer. **2022**, 13, 687-689 ○
- 101 Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications. **2022**, 14, 4653 ○
- 100 Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer. **2022**, 7, ○
- 99 Bibliometric analysis of global research trends on small-cell lung cancer (2012-2021). 12, ○
- 98 Predicting Anti-Cancer Drug Combination Responses with a Temporal Cell State Network Model. ○
- 97 Value of immunohistochemistry in crushed areas of pulmonary neuroendocrine carcinoma. **2022**, 104836 ○
- 96 Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment. **2022**, 1868, 166557 1
- 95 Histologic transformation in lung cancer: when one door shuts, another opens. **2022**, 14, 175883592211305 ○
- 94 The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime?. **2022**, 29, 7355-7378 1
- 93 Relapsed small-cell lung cancer: a disease of continued unmet need. **2022**, ○
- 92 Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma. Publish Ahead of Print, ○
- 91 Meta-analysis of preclinical pharmacogenomic studies to discover robust and translatable biomarkers of drug response. ○
- 90 SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. **2022**, ○
- 89 Extracellular vesicles from non-neuroendocrine SCLC cells promote adhesion and survival of neuroendocrine SCLC cells. ○

- 88 Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer. 12, ○
- 87 NDR1 activates CD47 transcription by increasing protein stability and nuclear location of ASCL1 to enhance cancer stem cell properties and evasion of phagocytosis in small cell lung cancer. **2022**, 39, ○
- 86 Brief report: Reclassifying SCLC-Y as SMARCA4 deficient malignancies - resolving the controversy. ○
- 85 Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. **2022**, 1
- 84 Spatial epitope barcoding reveals clonal tumor patch behaviors. **2022**, ○
- 83 Single Cell lineage Tracing Identifies Cancer Testis Antigens as Mediators of Chemoresistance in Small Cell Lung Cancer. ○
- 82 Lineage plasticity in SCLC generates non-neuroendocrine cells primed for vasculogenic mimicry. ○
- 81 Cancer of the Lung. 1-29 ○
- 80 Cancer bronchique à petites cellules : quoi de neuf ?. **2022**, 14, 2S244-2S251 ○
- 79 Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. ○
- 78 Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation. **2022**, 25, 105338 ○
- 77 Druggable Growth Dependencies and Tumor Evolution Analysis in Patient-Derived Organoids of Neuroendocrine Cancer. ○
- 76 Induced Degradation of Lineage-specific Oncoproteins Drives the Selective PARP1 Inhibitor Toxicity in Small Cell Lung Cancer. ○
- 75 Small-cell lung cancer transformation as a mechanism of resistance to pralsetinib in RET-rearranged lung adenocarcinoma: a case report. **2022**, ○
- 74 Extensive-Stage Small-Cell Lung Cancer: Current Management and Future Directions. ○
- 73 The prognostic impact of the immune microenvironment in small-cell neuroendocrine carcinoma of the uterine cervix: PD-L1 and immune cell subtypes. **2022**, 22, ○
- 72 BET Inhibitors Target the SCLC-N subtype of Small Cell Lung Cancer by Blocking NEUROD1 Transactivation. ○
- 71 Transcriptional Profiling Reveals Mesenchymal Subtypes of Small Cell Lung Cancer with Activation of the Epithelial-to-Mesenchymal Transition and Worse Clinical Outcomes. **2022**, 14, 5600 ○

70	DLL3 regulates Notch signaling in small cell lung cancer. 2022 , 105603	○
69	Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer. 2022 , 7, 100631	○
68	Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response. 2022 , 87, 117-126	○
67	Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities. 2022 , 13,	○
66	Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification. 2023 , 175, 88-100	○
65	The Many Faces of Muscle-Invasive Bladder Cancer: Histopathological and Molecular Characterization. 2023 , 33, 1-11	○
64	Small Cell Lung Carcinoma. 2022 , 733-739	○
63	Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. 2022 , 3, 1351-1366	2
62	An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC. 2022 ,	○
61	Molecular features and evolutionary trajectory of ASCL1+ and NEUROD1+ SCLC cells.	○
60	Pten loss expands the histopathological diversity and lineage plasticity of lung cancers initiated by Rb1/Trp53 deletion. 2022 ,	○
59	circPVT1 and PVT1 / AKT3 show a role in cell proliferation, apoptosis, and tumor subtype-definition in Small Cell Lung Cancer.	○
58	ATR inhibition augments the efficacy of lurbinectedin in small cell lung cancer.	○
57	Fortgeschrittenes kleinzelliges Lungenkarzinom: Subtypen sprechen auf Therapien unterschiedlich an.	○
56	Neuroendocrinology of the lung revealed by single-cell RNA sequencing. 11,	○
55	Harnessing DLL3 inhibition: From old promises to new therapeutic horizons. 9,	○
54	TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.	○
53	Multivalent state transitions shape the intratumoral composition of small cell lung carcinoma. 2022 , 8,	○

- 52 Heterogeneous expression and role of receptor tyrosine kinase-like orphan receptor 2 (ROR2) in small cell lung cancer. ○
- 51 All Together Now. **2022**, ○
- 50 Proposing Specific Neuronal Epithelial-to-Mesenchymal Transition Genes as an Ancillary Tool for Differential Diagnosis among Pulmonary Neuroendocrine Neoplasms. **2022**, 13, 2309 ○
- 49 Emerging Strategies for the Treatment of Small Cell Lung Cancer. ○
- 48 Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. 13, ○
- 47 Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer. **2022**, 54, 2118-2127 1
- 46 An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells. **2023**, 23, ○
- 45 Biomarqueurs des carcinomes pulmonaires à petites cellules en 2022. **2023**, 2022, 34-40 ○
- 44 MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. **2023**, 22, ○
- 43 Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. **2023**, 9, ○
- 42 A multiplexed in vivo approach to identify driver genes in small cell lung cancer. **2023**, 42, 111990 ○
- 41 Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer. 11, ○
- 40 Recent advances in small cell lung cancer: the future is now?. **2023**, 47, ○
- 39 Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer. **2023**, 159, 114248 ○
- 38 Model-Based Regional Control with Anomalous Diffusion of Multi-Drug Combined Cancer Therapy for Volume Predictions. **2023**, 15, 51 ○
- 37 Lung Tumors. **2021**, 353-596 ○
- 36 Molecular Pathology of Lung Tumors. **2021**, 633-669 ○
- 35 The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients. **2023**, 35, 100684 ○

- 34 Neuronal-Activity Dependent Mechanisms of Small Cell Lung Cancer Progression. ○
- 33 YAP1 and WWTR1 expression inversely correlate with neuroendocrine markers in Merkel cell carcinoma. ○
- 32 Small-cell lung cancer tumor microenvironment associated with molecular subtypes and platinum resistance. ○
- 31 Functional synapses between small cell lung cancer and glutamatergic neurons. ○
- 30 Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small-cell lung cancer: protocol of IRICO study. ○
- 29 Assessing the epithelial-to-mesenchymal plasticity in a small cell lung carcinoma (SCLC) and lung fibroblasts co-culture model. 10, ○
- 28 Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer. **2023**, 38, 218-225 ○
- 27 What Is New in Small Cell Lung Cancer. **2023**, ○
- 26 How Far Are We from Research That Is Independent of the Use of Animal Models? A Comparative Analysis between Animal and 3D/On-a-Chip Models for the Study of Respiratory Diseases. **2023**, 2, 157-172 ○
- 25 Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance. **2023**, 100184 ○
- 24 Neuroendocrine Neoplasms. **2023**, 18, 169-187 ○
- 23 Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy. **2023**, 179, 107183 ○
- 22 Junctional adhesion molecule 3 is a potential therapeutic target for small cell lung carcinoma. **2023**, 426, 113570 ○
- 21 Data-driven structural analysis of Small Cell Lung Cancer transcription factor network suggests potential subtype regulators and transition pathways. ○
- 20 Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. **2022**, 1-34 ○
- 19 Characterization of the microenvironment in different immune-metabolism subtypes of cervical cancer with prognostic significance. 14, ○
- 18 Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours. **2023**, 32, 220174 ○
- 17 CRACD, a gatekeeper restricting proliferation, heterogeneity, and immune evasion of small cell lung cancer. ○

- 16 The pulmonary neuroepithelial body microenvironment represents an underestimated multimodal component in airway sensory pathways. ○
- 15 Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility. **2023**, 6, e230698 ○
- 14 An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1 -positive neuroendocrine carcinoma. ○
- 13 Involvement of Epithelial-Mesenchymal Transition Genes in Small Cell Lung Cancer Phenotypic Plasticity. **2023**, 15, 1477 ○
- 12 Potential value of efficacy prediction and treatment of natural killer cells in extensive stage small cell lung cancer. **2023**, 14, 864-872 ○
- 11 Mapping the immune landscape in small cell lung cancer by analysing expression of immuno-modulators in tissue biopsies and paired blood samples. **2023**, 13, ○
- 10 Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer. ○
- 9 Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications. **2023**, 184, 103966 ○
- 8 Phenotypic plasticity promotes lymph nodes metastasis and drug resistance in lung squamous cell carcinomas. **2023**, 9, e14614 ○
- 7 Genetic variants of NEUROD1 target genes are associated with clinical outcomes of small-cell lung cancer patients. ○
- 6 Onionin A inhibits small-cell lung cancer proliferation through suppressing STAT3 activation induced by macrophages-derived IL-6 and cell-cell interaction with tumor-associated macrophage. **2023**, 36, 1068-1080 ○
- 5 Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer. 14, ○
- 4 The functional and clinical roles of liquid biopsy in patient-derived models. **2023**, 16, ○
- 3 MYC activation impairs cell-intrinsic IFN β signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. **2023**, 4, 101006 ○
- 2 Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis. ○
- 1 MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat. **2023**, 42, ○